Table 4.
Ultra test alone |
Addition of signature to: |
|||
---|---|---|---|---|
All Ultra-positive individuals | Ultra trace-positive individuals | Ultra-positive individuals with previous tuberculosis | ||
Sensitivity | ||||
BATF2 | 82% (69–90) | 76% (63–86) | 82% (69–90) | 80% (67–89) |
Kaforou25 | .. | 66% (52–78); p=0·013 | 82% (69–90) | 74% (60–84) |
Roe3 | .. | 78% (65–87) | 82% (69–90) | 80% (67–89) |
Sweeney3 | .. | 76% (63–86) | 80% (67–89) | 78% (65–87) |
Specificity | ||||
BATF2 | 90% (83–95) | 99% (95–100); p=0·0077 | 95% (89–98) | 96% (91–98); p=0·041 |
Kaforou25 | .. | 100% (96–100); p=0·0044 | 96% (91–98); p=0·041 | 97% (92–99); p=0·023 |
Roe3 | .. | 99% (95–100); p=0·0077 | 95% (89–98) | 96% (91–98); p=0·041 |
Sweeney3 | .. | 100% (96–100); p=0·0044 | 96% (91–98); p=0·041 | 97% (92–99); p=0·023 |
Data are % (95% CI). Only significant p values are shown. Sensitivity and specificity were calculated for 154 patients with Ultra results, with or without reclassification of selected Ultra-positive tests by transcriptional signatures. p value of comparison with Ultra alone using McNemar's test.